<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Alfa-Galactosyl <z:chebi fb="7" ids="17761">Ceramide</z:chebi> was isolated from Ocean sponge which has antitumor effect against several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in in vivo animal model with no cytotoxicity </plain></SENT>
<SENT sid="1" pm="."><plain>KRN7000(KRN) is the most potent alpha-Galactosyl <z:chebi fb="7" ids="17761">Ceramide</z:chebi> modified from the one isolated from Ocean sponge </plain></SENT>
<SENT sid="2" pm="."><plain>KRN is also active against <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> through the activation ofanimal immune system </plain></SENT>
<SENT sid="3" pm="."><plain>Research efforts in learning the mechanism of action, we found the important role of dendritic cells(DC) and NKT cells </plain></SENT>
<SENT sid="4" pm="."><plain>NKT cells was first characterized in 1988 which is overlap some part with NK cells and T-Cells and majority is different from NK and T </plain></SENT>
<SENT sid="5" pm="."><plain>KRN is active through the activation of DC and NKT in giving antigen specific immune stimulation in animal </plain></SENT>
<SENT sid="6" pm="."><plain>This antigen specific stimulation is memorized by immune system and can reject second <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> challenge </plain></SENT>
<SENT sid="7" pm="."><plain>KRN is not active in <z:mp ids='MP_0003815'>nude</z:mp> mice and NKT deficient animal </plain></SENT>
<SENT sid="8" pm="."><plain>NKT cells level in blood is lower in patients with <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo>, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, HIV positive or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>NKT rapidly releases IL-4 and IFN-gamma at high level when activated </plain></SENT>
<SENT sid="10" pm="."><plain>NKT is CD1d and TCR restricted </plain></SENT>
<SENT sid="11" pm="."><plain>NKT plays important role in <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> such as Type 1 <z:mp ids='MP_0002055'>Diabetes</z:mp>, <z:hpo ids='HP_0100324'>Scleroderma</z:hpo> and <z:hpo ids='HP_0002725'>Systemic Lupus Erythematosus</z:hpo>, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> such as Mycobacteria, Listeria and <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">Malaria</z:e>, GVHD control and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> rejection </plain></SENT>
<SENT sid="12" pm="."><plain>NKT acts as double edge sword, aggressive and suppressive ways </plain></SENT>
<SENT sid="13" pm="."><plain>KRN can prevent the <z:hpo ids='HP_0003674'>onset</z:hpo> of Type 1 <z:mp ids='MP_0002055'>Diabetes</z:mp>, inhibit replication of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> virus B in liver and suppress <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> replication in activating NKT cells </plain></SENT>
<SENT sid="14" pm="."><plain>KRN can activate NKT through DC and activated NKT activates NK, T and macrophage </plain></SENT>
<SENT sid="15" pm="."><plain>KRN also expands NKT cells and expanded NKT has full function </plain></SENT>
<SENT sid="16" pm="."><plain>Although the exact role of DC and NKT is not clear, KRN clinical study results in conjunction with DC and NKT cell activation are expected </plain></SENT>
</text></document>